Relief Therapeutics - eine COVID-19 Hoffnung? (Seite 310)
eröffnet am 11.03.20 17:46:44 von
neuester Beitrag 05.04.24 14:53:43 von
neuester Beitrag 05.04.24 14:53:43 von
Beiträge: 14.078
ID: 1.321.697
ID: 1.321.697
Aufrufe heute: 19
Gesamt: 2.517.961
Gesamt: 2.517.961
Aktive User: 0
ISIN: CH1251125998 · WKN: A3EFB5 · Symbol: RLF
1,2850
CHF
+1,98 %
+0,0250 CHF
Letzter Kurs 17:30:49 SIX Swiss (CHF)
Neuigkeiten
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,4800 | +33,82 | |
| 4,7200 | +28,26 | |
| 7,2000 | +24,78 | |
| 2,7700 | +22,03 | |
| 0,7621 | +22,01 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,7603 | -15,56 | |
| 2,8900 | -18,36 | |
| 0,6575 | -20,77 | |
| 27,00 | -49,30 | |
| 3,3850 | -54,01 |
Beitrag zu dieser Diskussion schreiben
Feedback
Antwort auf Beitrag Nr.: 70.081.178 von nuno9999 am 01.12.21 07:43:25Da war jemand schneller…
:-)
:-)
Antwort auf Beitrag Nr.: 70.081.124 von Kostolany76 am 01.12.21 07:35:13
The rapid clinical improvement was seen in the first patient, treated with RLF-100 (Aviptadil). The hypothesis is that VIP defends AT-II cells, prevents cytokine storm, and increases oxygenation in a threatening lung. When the lungs are manifested with SARS-CoV-2 infection, VIP plays a critical role. Rapid recovery was reported in patients on ventilators and ECMO (extracorporeal membrane oxygenation), with various medical histories, after 3 days of FDA emergency treatment with RLF-100, with IND approval at multiple clinical sites. Aviptadil is the first vasoactive intestinal peptide that is being created to inhibit replication of the SARS-CoV-2 virus in the host cell including monocytes, as the first COVID-19 therapy. RLF-100 or Aviptadil is a synthetic human VIP that has also been patented. It is also granted with fast tracer designation. All the evident data, published based on clinical trials, seem to be very fruitful in defining a pharmacological guideline for COVID care. In recent clinical trials, the overall target result is that there is a tremendous improvement in life expectancy, by optimizing oxygenation and surveilling cytokine storm in COVID-19–induced respiratory failure.[i][/i]
The rapid clinical improvement was seen in the first patient, treated with RLF-100 (Aviptadil). The hypothesis is that VIP defends AT-II cells, prevents cytokine storm, and increases oxygenation in a threatening lung. When the lungs are manifested with SARS-CoV-2 infection, VIP plays a critical role. Rapid recovery was reported in patients on ventilators and ECMO (extracorporeal membrane oxygenation), with various medical histories, after 3 days of FDA emergency treatment with RLF-100, with IND approval at multiple clinical sites. Aviptadil is the first vasoactive intestinal peptide that is being created to inhibit replication of the SARS-CoV-2 virus in the host cell including monocytes, as the first COVID-19 therapy. RLF-100 or Aviptadil is a synthetic human VIP that has also been patented. It is also granted with fast tracer designation. All the evident data, published based on clinical trials, seem to be very fruitful in defining a pharmacological guideline for COVID care. In recent clinical trials, the overall target result is that there is a tremendous improvement in life expectancy, by optimizing oxygenation and surveilling cytokine storm in COVID-19–induced respiratory failure.[i][/i]
Antwort auf Beitrag Nr.: 70.081.124 von Kostolany76 am 01.12.21 07:35:13Hier ein Auszug
Conclusion
The rapid clinical improvement was seen in the first patient, treated with RLF-100 (Aviptadil). The hypothesis is that VIP defends AT-II cells, prevents cytokine storm, and increases oxygenation in a threatening lung. When the lungs are manifested with SARS-CoV-2 infection, VIP plays a critical role. Rapid recovery was reported in patients on ventilators and ECMO (extracorporeal membrane oxygenation), with various medical histories, after 3 days of FDA emergency treatment with RLF-100, with IND approval at multiple clinical sites. Aviptadil is the first vasoactive intestinal peptide that is being created to inhibit replication of the SARS-CoV-2 virus in the host cell including monocytes, as the first COVID-19 therapy. RLF-100 or Aviptadil is a synthetic human VIP that has also been patented. It is also granted with fast tracer designation. All the evident data, published based on clinical trials, seem to be very fruitful in defining a pharmacological guideline for COVID care. In recent clinical trials, the overall target result is that there is a tremendous improvement in life expectancy, by optimizing oxygenation and surveilling cytokine storm in COVID-19–induced respiratory failure.
Conclusion
The rapid clinical improvement was seen in the first patient, treated with RLF-100 (Aviptadil). The hypothesis is that VIP defends AT-II cells, prevents cytokine storm, and increases oxygenation in a threatening lung. When the lungs are manifested with SARS-CoV-2 infection, VIP plays a critical role. Rapid recovery was reported in patients on ventilators and ECMO (extracorporeal membrane oxygenation), with various medical histories, after 3 days of FDA emergency treatment with RLF-100, with IND approval at multiple clinical sites. Aviptadil is the first vasoactive intestinal peptide that is being created to inhibit replication of the SARS-CoV-2 virus in the host cell including monocytes, as the first COVID-19 therapy. RLF-100 or Aviptadil is a synthetic human VIP that has also been patented. It is also granted with fast tracer designation. All the evident data, published based on clinical trials, seem to be very fruitful in defining a pharmacological guideline for COVID care. In recent clinical trials, the overall target result is that there is a tremendous improvement in life expectancy, by optimizing oxygenation and surveilling cytokine storm in COVID-19–induced respiratory failure.
Antwort auf Beitrag Nr.: 70.081.124 von Kostolany76 am 01.12.21 07:35:13
The rapid clinical improvement was seen in the first patient, treated with RLF-100 (Aviptadil). The hypothesis is that VIP defends AT-II cells, prevents cytokine storm, and increases oxygenation in a threatening lung. When the lungs are manifested with SARS-CoV-2 infection, VIP plays a critical role. Rapid recovery was reported in patients on ventilators and ECMO (extracorporeal membrane oxygenation), with various medical histories, after 3 days of FDA emergency treatment with RLF-100, with IND approval at multiple clinical sites. Aviptadil is the first vasoactive intestinal peptide that is being created to inhibit replication of the SARS-CoV-2 virus in the host cell including monocytes, as the first COVID-19 therapy. RLF-100 or Aviptadil is a synthetic human VIP that has also been patented. It is also granted with fast tracer designation. All the evident data, published based on clinical trials, seem to be very fruitful in defining a pharmacological guideline for COVID care. In recent clinical trials, the overall target result is that there is a tremendous improvement in life expectancy, by optimizing oxygenation and surveilling cytokine storm in COVID-19–induced respiratory failure.
The rapid clinical improvement was seen in the first patient, treated with RLF-100 (Aviptadil). The hypothesis is that VIP defends AT-II cells, prevents cytokine storm, and increases oxygenation in a threatening lung. When the lungs are manifested with SARS-CoV-2 infection, VIP plays a critical role. Rapid recovery was reported in patients on ventilators and ECMO (extracorporeal membrane oxygenation), with various medical histories, after 3 days of FDA emergency treatment with RLF-100, with IND approval at multiple clinical sites. Aviptadil is the first vasoactive intestinal peptide that is being created to inhibit replication of the SARS-CoV-2 virus in the host cell including monocytes, as the first COVID-19 therapy. RLF-100 or Aviptadil is a synthetic human VIP that has also been patented. It is also granted with fast tracer designation. All the evident data, published based on clinical trials, seem to be very fruitful in defining a pharmacological guideline for COVID care. In recent clinical trials, the overall target result is that there is a tremendous improvement in life expectancy, by optimizing oxygenation and surveilling cytokine storm in COVID-19–induced respiratory failure.
Antwort auf Beitrag Nr.: 70.081.124 von Kostolany76 am 01.12.21 07:35:13Conclusion
The rapid clinical improvement was seen in the first patient, treated with RLF-100 (Aviptadil). The hypothesis is that VIP defends AT-II cells, prevents cytokine storm, and increases oxygenation in a threatening lung. When the lungs are manifested with SARS-CoV-2 infection, VIP plays a critical role. Rapid recovery was reported in patients on ventilators and ECMO (extracorporeal membrane oxygenation), with various medical histories, after 3 days of FDA emergency treatment with RLF-100, with IND approval at multiple clinical sites. Aviptadil is the first vasoactive intestinal peptide that is being created to inhibit replication of the SARS-CoV-2 virus in the host cell including monocytes, as the first COVID-19 therapy. RLF-100 or Aviptadil is a synthetic human VIP that has also been patented. It is also granted with fast tracer designation. All the evident data, published based on clinical trials, seem to be very fruitful in defining a pharmacological guideline for COVID care. In recent clinical trials, the overall target result is that there is a tremendous improvement in life expectancy, by optimizing oxygenation and surveilling cytokine storm in COVID-19–induced respiratory failure.
The rapid clinical improvement was seen in the first patient, treated with RLF-100 (Aviptadil). The hypothesis is that VIP defends AT-II cells, prevents cytokine storm, and increases oxygenation in a threatening lung. When the lungs are manifested with SARS-CoV-2 infection, VIP plays a critical role. Rapid recovery was reported in patients on ventilators and ECMO (extracorporeal membrane oxygenation), with various medical histories, after 3 days of FDA emergency treatment with RLF-100, with IND approval at multiple clinical sites. Aviptadil is the first vasoactive intestinal peptide that is being created to inhibit replication of the SARS-CoV-2 virus in the host cell including monocytes, as the first COVID-19 therapy. RLF-100 or Aviptadil is a synthetic human VIP that has also been patented. It is also granted with fast tracer designation. All the evident data, published based on clinical trials, seem to be very fruitful in defining a pharmacological guideline for COVID care. In recent clinical trials, the overall target result is that there is a tremendous improvement in life expectancy, by optimizing oxygenation and surveilling cytokine storm in COVID-19–induced respiratory failure.
Trading Spotlight
Antwort auf Beitrag Nr.: 70.081.124 von Kostolany76 am 01.12.21 07:35:13Ich versuche es nochmals mit dem Link
https://link.springer.com/article/10.1007/s11356-021-17824-5
https://link.springer.com/article/10.1007/s11356-021-17824-5
Alp
Was steht da drin?Geht bei mir nicht auf…
Lars5 minutes ago
Anticipated pharmacological role of Aviptadil on COVID-19
https://link.springer.com/article/10.1007/s11356-021-17824-5
Anticipated pharmacological role of Aviptadil on COVID-19
https://link.springer.com/article/10.1007/s11356-021-17824-5
https://clinicaltrials.gov/ct2/show/NCT05137795?term=aviptad…
AVICOVID-3 Inhaled Use of Zyesami for Treatment of Severe COVID-19 (AVICOVID-2)
Neue Studie für Inhaled Zyesami in Georgien. Studienpartner ist unter anderem das Lugar Research Center. Wer die Videos von Dr.Joey gesehen hat weiss um was es sich da handelt.
AVICOVID-3 Inhaled Use of Zyesami for Treatment of Severe COVID-19 (AVICOVID-2)
Neue Studie für Inhaled Zyesami in Georgien. Studienpartner ist unter anderem das Lugar Research Center. Wer die Videos von Dr.Joey gesehen hat weiss um was es sich da handelt.
Relief Therapeutics ernennt Nermeen Varawalla zur neuen Chief Medical Officer
Das Westschweizer Biotechunternehmen Relief Therapeutics nimmt in der Geschäftsleitung mehrere Anpassungen vor. Allen voran wurde Nermeen Varawalla zur neuen Chief Medical Officer ernannt. Sie übernehme die Nachfolge von Gilles Della Corte, der das Unternehmen verlasse, teilte Relief am Dienstag mit.
Varawalla bringe langjähriges Know-how in den Bereichen klinische Studien und medizinische Themen mit in die Geschäftsleitung ein, heisst es weiter. Sie habe in verschiedenen Firmen klinische Entwicklungsprogramme geleitet und Arzneimittel bis zur Markteinführung begleitet. Zuletzt war sie bei Atlantic Healthcare tätig, einem auf Medikamenten zur Behandlung von Darmerkrankungen spezialisierten Pharmaunternehmen.
Weiter hat Relief Marco Marotta zum Chief Business Officer und Jeremy Meinen zum Chief Accounting Officer ernannt. Marotta stiess mit der in diesem Jahr vollzogenen Übernahme von APR Applied Pharma Research zu den Genfern. Er sei für die Geschäftsentwicklung, einschliesslich den strategischen Partnerschaften, von Relief verantwortlich, heisst es. Jeremy Meinen war zuletzt im Finanzbereich des Unternehmens tätig.
mk/hr
(AWP)
Das Westschweizer Biotechunternehmen Relief Therapeutics nimmt in der Geschäftsleitung mehrere Anpassungen vor. Allen voran wurde Nermeen Varawalla zur neuen Chief Medical Officer ernannt. Sie übernehme die Nachfolge von Gilles Della Corte, der das Unternehmen verlasse, teilte Relief am Dienstag mit.
Varawalla bringe langjähriges Know-how in den Bereichen klinische Studien und medizinische Themen mit in die Geschäftsleitung ein, heisst es weiter. Sie habe in verschiedenen Firmen klinische Entwicklungsprogramme geleitet und Arzneimittel bis zur Markteinführung begleitet. Zuletzt war sie bei Atlantic Healthcare tätig, einem auf Medikamenten zur Behandlung von Darmerkrankungen spezialisierten Pharmaunternehmen.
Weiter hat Relief Marco Marotta zum Chief Business Officer und Jeremy Meinen zum Chief Accounting Officer ernannt. Marotta stiess mit der in diesem Jahr vollzogenen Übernahme von APR Applied Pharma Research zu den Genfern. Er sei für die Geschäftsentwicklung, einschliesslich den strategischen Partnerschaften, von Relief verantwortlich, heisst es. Jeremy Meinen war zuletzt im Finanzbereich des Unternehmens tätig.
mk/hr
(AWP)
Durchsuchen
Relief Therapeutics - eine COVID-19 Hoffnung?
